DRUG · Unmapped registry intervention
Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
Find medicine records ·
Find other trials using this name
Clinical trial
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT06071013
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedNintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
EGFR Gene Mutationunresolved
EGFR-TKI Resistant Mutationunresolved
Interventions
Sponsors & collaborators
China Medical University Hospitallead sponsor
China Medical University, Taiwancollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06071013 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.